Madrigal Pharmaceuticals valuation
$421.99Change from previous close: −0.46%Absolute change: −$1.97
Valuation
The average price target of 18 analysts is $688.78.
Data as of November 16, 2026
Madrigal Pharmaceuticals compared with similar companies
Madrigal Pharmaceuticals's Forward P/E: 38.1, +143% against the median of a group of 7 similar companies (15.7).
| Metric | Madrigal Pharmaceuticals | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| Forward P/E | 38.1 | 15.7 | 9.12 – 24.0 | High |
| Price/book | 15.8 | 15.7 | 5.28 – 18.1 | Middle |
| Price/sales | 6.95 | 8.41 | 6.66 – 15.9 | Middle |
| Gross margin | 91.0% | 91.0% | 59.7% – 95.3% | Middle |
| Operating margin | -10.7% | 0.8% | -19.7% – 24.5% | Middle |
| Net margin | -10.9% | 0.0% | -5.7% – 10.3% | Low |
| ROE | -24.8% | 8.2% | -9.7% – 38.5% | Low |
| Debt/equity | 0.56 | 0.12 | 0.02 – 0.62 | Middle |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Other metrics
Valuation multiples
- Market cap
- $9.93B
- Enterprise value
- $9.32B
- P/E (trailing 12 months)
- -30.1
- EV/EBITDA
- -61.7
- EV/revenue
- 6.53
Profitability and growth
- ROA
- -6.8%
- ROIC
- -23.8%
- Revenue growth (year over year)
- 50.1%
- Earnings growth (year over year)
- 31.9%
Financial health
- Total cash
- $960.97M
- Total debt
- $354.22M
- Current ratio
- 3.05
- Quick ratio
- 2.62
- Altman Z-Score
- 7.92
- Piotroski F-Score
- 1.00
Dividends
- Dividend yield
- 0.0%
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $688.78
- Median price target
- $660.00
- High price target
- $962.00
- Low price target
- $479.00
- Analysts with a price target
- 18
- Consensus
- Strong buy
- Forward EPS
- $11.21
- EPS estimate, current year
- -$2.00
Shares and trading
- Beta
- -1.00
- Average volume
- 355.87K
- Shares outstanding
- 23.23M
- Float
- 13.96M
- Institutional ownership
- 104.7%
- Insider ownership
- 6.4%
- Short interest (% of float)
- 10.8%
- Short ratio (days)
- 7.25
